UBS Initiates Coverage On Bio-Rad Laboratories with Buy Rating, Announces Price Target of $395
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Dan Leonard has initiated coverage on Bio-Rad Laboratories (NYSE:BIO) with a Buy rating and set a price target of $395.
December 07, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has initiated coverage on Bio-Rad Laboratories with a Buy rating and a price target of $395.
Analyst coverage, especially with a Buy rating, tends to create positive sentiment around a stock. The price target of $395 suggests a potential upside from the current trading price, which could attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100